[1]蔡敏,李险峰,陈海滨,等.131Ⅰ治疗Graves病783例疗效观察及影响因素分析[J].国际放射医学核医学杂志,2008,32(2):75-78.
　CAI Min,LI Xian-feng,CHEN Hai-bin,et al.Multiple factor analysis of the therapeutic effect of 131Ⅰ in treating 783 cases of Graves disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):75-78.
点击复制

131Ⅰ治疗Graves病783例疗效观察及影响因素分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
32
期数:
2008年第2期
页码:
75-78
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Multiple factor analysis of the therapeutic effect of 131Ⅰ in treating 783 cases of Graves disease
作者:
蔡敏1;  李险峰1;  陈海滨2;  李思进1
1. 030001 太原, 山西医科大学第一医院核医学科;
2. 030001 太原, 山西医科大学第二医院药品临床评价中心
Author(s):
CAI Min1;  LI Xian-feng1;  CHEN Hai-bin2;  LI Si-jin1
1. Department of Nuclear Medicine, The First Hospital, Shanxi Medical University, Taiyuan 030001, China;
2. The Clinical Drug Evaluation Center of the Second Hospital, Shanxi Medical University, Taiyuan 030001, China
关键词:
GRAVES病; 甲状腺功能亢进症; 碘放射性同位素; 近距离放射疗法
Keywords:
Graves disease; Hyperthyroidism; Iodine radioisotope; Brachytherapy
摘要:
目的 观察131Ⅰ治疗甲状腺功能亢进症(甲亢)的疗效及分析影响因素。方法 Graves病患者783例,服用131Ⅰ前记录患者性别、年龄、病程、甲状腺肿大程度和性质、甲亢程度、服用抗甲状腺药(ATD)情况、甲状腺质量、有否结节、24h摄131Ⅰ率、131Ⅰ总剂量、每克甲状腺给予131Ⅰ剂量、血清甲状腺激素及甲状腺自身抗体水平,量化各指标值,治疗3、6、12及24个月后分别观察患者症状和体征的变化情况,按完全缓解(包括甲状腺功能减退症)、部分缓解进行评价。统计分析使用SAS8.2软件包,采用CMH卡方检验(CMH χ2)、Wilcoxon秩和检验及Logistic回归。结果 疗效与服用131Ⅰ后的时间存在线性关系(CMHχ2=69.21,P<0.01);服用131Ⅰ12个月后甲状腺质量、急躁、易惊、食欲亢进、心悸等症状和体征均有明显的改善(P值均<0.05);Logistic回归结果显示:年龄、甲状腺24h摄131Ⅰ率、甲状腺质量、每克甲状腺组织131Ⅰ剂量、结节对疗效的影响有统计学意义(P值均<0.05)。结论 服用131Ⅰ后随访期内疗效较好,甲状腺质量、急躁、易惊、食欲亢进、心悸等症状和体征明显改善。对于年龄偏大、甲状腺24h摄131Ⅰ率高、甲状腺质量大、甲状腺有结节的患者,疗效较差,应适当增加服131Ⅰ剂量;反之,应减少。
Abstract:
Objective To study the factors influencing therapeutic effect of 131Ⅰ in treating 783 cases of Graves disease. Methods The values of various indexes were quantized on influencing factors such as age, sex, course of disease, mass of thyroid gland, the absorbed dose of 131Ⅰ per gram of thryoid gland, the given dose of 131Ⅰ, thyroid 24 h 131Ⅰ uptaking percentage, thyroid hormone and thyroid autoantibodys. The assessment of the therapeutic effect was made according to complete remission (including hypothyroidism) and partial remission after 131Ⅰ therapy. CMH χ2, Wilcoxon signed-rank test and Logistic regression were used to analyze the variable parameters before the treatment. Results The therapeutic effect of 131Ⅰ is significant in the follow-up period (CMHχ2=69.21, P<0.01). The mass of thyroid, rashness, bulimia, etc, were relieved significantly(all the values of P<0.05) after 131Ⅰ therapy for 12 months. The therapeutic effect was related to such factors as age thyroid mass, the absorbed dose of 131Ⅰ per gram of thryoid gland, thyroid 24 h 131Ⅰ uptaking percentage, etc (all the values of P<0.05). Conclusion In those older patients and those whose thyroid 24 h 131Ⅰ uptaking percentage is higher, thyroid mass is bigger, thyroid gland is with noduses, the given dose of 131Ⅰ should be increased. Conversely decreased.

参考文献/References:

[1] 张永学.核医学[M].北京:人民卫生出版社,2005:355,189,393.
[2] 武海明,谭天秩,匡安仁,等.131I治疗Graves甲亢疗效影响因素的研究[J].中华核医学杂志,2003,23(5):291-293.
[3] 郭一玲,冯程,汤学民,等.影响131I治疗甲状腺功能亢进效果及剂量因素分析[J].中国地方病学杂志,2004,23(3):248-250.
[4] 唐武儒,刁丽娜,韦南仕,等.131I治疗225例甲亢患者的疗效分析[J].标记免疫分析与临床,2006,13(1):57-58.
[5] 方毅,刘剑锋,张友仁,等.131I治疗甲亢后61例早发甲状腺功能减低分析[J].解放军医学杂志,2004,29(2):168-169.
[6] 庞华,谭本旭,罗加.131I治疗Graves病疗效影响因素分析[J].中华核医学杂志,2003,23(6):337-338.
[7] Veliz J, Plineda G, Arancibia P, et al. Treatment of diffuse hyperthyroid goiter with radioiodine:influence of propylthiouracil pretreatment[J]. Rev Med Chil, 2000, 128(8):609-612.
[8] 耿建,陈勇,计学理,等.131Ⅰ治疗Graves病320例疗效影响因素分析[J].山西职工医学院学报,2005,15(1):16-18.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[6]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[7]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
　ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[8]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
　HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
[9]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
　MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
[10]王春梅,王雪梅.131I治疗甲亢的现状和研究进展[J].国际放射医学核医学杂志,2010,34(1):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
　WANG Chun-mei,WANG Xue-mei.The development and current status of 131I treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]

备注/Memo

备注/Memo:
收稿日期:2007-11-27。
通讯作者:蔡敏(E-mail:c.mll13@163.com)
更新日期/Last Update: 1900-01-01